Table of Contents
What changed
Revenue fell NZ$19.1m (-13.6%) to NZ$121.7m, but operating EBITDA contracted more sharply, down NZ$4.4m (-26.6%) to NZ$12.2m, indicating meaningful negative operating leverage. PBT declined 18.3% to NZ$5.0m. NPAT of NZ$4.3m was nearly flat (-2.9%) only because the effective tax rate fell to 12.9% from 26.4%, reducing the tax charge from NZ$1.6m to NZ$0.6m — a cushion that will not automatically repeat.
The revenue decline was concentrated in the Americas (down NZ$19.3m, share falling from 31% to 22%) and Australia (down NZ$9.8m, share from 15.7% to 11.1%). Europe partially offset this, growing NZ$4.2m to NZ$52.0m and becoming the dominant segment at 38.4% of revenue. Europe's segment margin held at roughly 13.2%, and Australia's margin actually improved sharply to ~7.4% on lower revenue, suggesting a quality-over-volume shift. The Rocklabs Manufacturing segment contributed NZ$23.9m at a strong ~25.4% margin, though no prior-period comparable was disclosed in the same format.
On the balance sheet, gross borrowings fell NZ$8.7m to NZ$25.5m, reducing net debt to approximately NZ$13.2m and leverage to ~1.1x EBITDA. Operating cash flow swung from an outflow of NZ$7.7m to an inflow of NZ$14.5m, with capex also dropping sharply from NZ$5.1m to NZ$1.1m. The interim dividend was cut 40% to NZ$0.03 per share.
What matters
The EBITDA-to-revenue leverage gap is the central concern. A 13.6% revenue decline produced a 26.6% EBITDA fall, implying a meaningful fixed-cost base that will continue to weigh if volumes do not recover. The NPAT line flatters this picture materially — PBT is the cleaner read, and it fell 18.3%.
The cash flow improvement is partially structural, partially reversible. Operating cash flow of NZ$14.5m looks strong relative to EBITDA of NZ$12.2m (119% conversion), but receivable days lengthened to 60.2 from 46.4 and inventory days rose to 55.4 from 46.9. The working-capital proxy grew NZ$5.1m to NZ$77.3m. Cash generation was aided by capex falling to just NZ$1.1m from NZ$5.1m — a level that appears unsustainably low relative to the business's geographic and operational footprint, and which may reverse in the second half.
Forward work is flat, not growing. The NZ$165m pipeline is unchanged from the prior period. Against an annualised revenue run-rate of NZ$243.5m, that equates to roughly 8 months of revenue cover, which is supportive but not signalling acceleration. The Destination 2030 target of NZ$530m revenue requires approximately 16.8% CAGR from the current run-rate — a significant lift from a period where revenue contracted.
Expectations
No explicit FY25 earnings guidance was provided. The release characterises the result as "stable net profit" and points to strengthening margins, reduced debt, and a strategic focus on higher-margin contracts.
Based on the FY24 full-year shape, the first half has historically carried more EBITDA weight (HY24 was 62.8% of FY24 EBITDA), meaning the implied second half from FY24 was only NZ$9.8m EBITDA. If a similar second-half profile applies to FY25, full-year EBITDA would be in the range of NZ$22m — materially below FY24's NZ$26.4m. That said, management's stated focus on higher-margin contracts and European momentum provides some basis for a better mix outcome, and the Destination 2030 strategy update at the upcoming investor day may reset the forward shape.
The dividend cut to NZ$0.03 per share (from NZ$0.05) is consistent with capital discipline given the earnings trajectory. The full-year dividend total will depend on the final dividend; the FY24 final was NZ$0.03 per share, so the full-year FY25 payout is not yet determinable.
Quality of result
The NPAT figure of NZ$4.3m is lower quality than it appears. The 12.9% effective tax rate provided approximately NZ$1.0m of bottom-line support relative to a normalised rate, and the filing does not explain the driver — whether deferred tax movements, jurisdictional mix, or a one-off item. This tax benefit may not repeat.
The operating cash flow improvement, while real, is partially timing and capex-driven. Receivable days extending 13.8 days signals that cash has been collected from prior-period work, not necessarily from accelerating new billings. Low capex of NZ$1.1m (0.9% of revenue versus 3.6% prior half) looks like near-term restraint rather than a sustainably lower maintenance requirement for a global manufacturing and automation business.
What does look durable: the leverage reduction to ~1.1x EBITDA is genuine and gives the company financial flexibility. Europe's margin stability and Rocklabs' strong margins suggest the mix-toward-quality strategy is having some effect. The Americas revenue decline is large but the company has framed it as deliberate selectivity.
Unresolved
- The driver of the 12.9% effective tax rate is not explained; without this, the sustainability of NPAT flatness is unclear.
- Capex at NZ$1.1m is materially below the prior period's NZ$5.1m with no stated rationale — whether this reflects project timing, deliberate restraint, or deferred maintenance is unresolved.
- No segment-level prior-period comparisons were provided for New Zealand Manufacturing and Rocklabs Manufacturing following the reporting re-cut, making it impossible to assess year-on-year trend quality in those units.
- The Americas revenue decline of NZ$19.3m is attributed to margin selectivity, but no evidence of replacement pipeline in that geography is disclosed.
- The Destination 2030 strategy is described as forthcoming — the current result provides no visibility into what organic or inorganic levers management intends to pull to bridge from NZ$243.5m annualised to NZ$530m.
This briefing cannot assess whether the low effective tax rate reflects a sustainable jurisdictional benefit or a non-recurring item, nor can it evaluate the updated Destination 2030 strategy targets ahead of the investor day presentation.
Key metrics
| Metric | HY25 | HY24 | Change |
|---|---|---|---|
| Revenue | $121.7m | $140.9m | -13.6% ↓ |
| EBITDA | $12.2m | $16.6m | -26.6% ↓ |
| Net profit after tax | $4.3m | $4.4m | -2.9% ↓ |
| Net cash inflow from operating activities | $14.5m | −$7.7m | +288.2% ↑ |
| Interim dividend per share | 3.0c | 5.0c | -40.0% ↓ |
| Profit before tax | $5.0m | $6.1m | -18.3% ↓ |
| Total assets | $244.4m | $255.8m | -4.5% ↓ |
Source: annolyse.ai/briefings/sct-hy25
Segment breakdown
| Segment | Current revenue | Prior revenue | Current result | Mix shift |
|---|---|---|---|---|
| New Zealand Manufacturing | $6.2m | — | $2.4m | n/a |
| Rocklabs Manufacturing | $23.9m | — | $6.1m | n/a |
| Australia Manufacturing | $15.0m | $24.8m | $1.1m | -4.6pp |
| Americas Manufacturing | $29.7m | $49.0m | $0.8m | -9.0pp |
| Europe Manufacturing | $52.0m | $47.8m | $6.9m | +8.2pp |
| China Manufacturing | $8.5m | $7.4m | $1.0m | +1.6pp |
Source: annolyse.ai/briefings/sct-hy25
Analytical metrics
| Metric | HY25 | HY24 | Context |
|---|---|---|---|
| PBT growth | -18.3% | — | cleaner earnings measure |
| Effective tax rate | 12.9% | 26.4% | — |
| OCF / EBITDA (cash conversion) | 119.3% | -46.5% | stable |
| FCF pre-lease | $13.4m | −$12.8m | +$26.2m |
| FCF / NPAT | 310.8% | -288.2% | complementary conversion metric |
| Capex % revenue | 0.9% | 3.6% | — |
| Capex | −$1.1m | −$5.1m | +$4.0m |
| Debtor days | 60.2 | 46.4 | +13.8 days |
| Inventory days | 55.4 | 46.9 | +8.5 days |
| Operating working capital | $77.3m | $72.2m | +$5.1m absorbed |
| Trade debtors | $40.3m | $35.9m | +$4.4m |
| Net debt | $13.2m | $20.7m | −$7.5m |
| Net debt / EBITDA | 1.08x | 1.25x | Strengthening |
| Gross borrowings | $25.5m | $34.2m | −$8.7m |
| Payout ratio vs NPAT | 55.6% | — | — |
| Payout ratio vs FCF pre-lease | 17.9% | — | covered |
| ROE (annualised) | 3.6% | 3.9% | Weakening |
| HY24 share of FY24 revenue | 51.0% | — | Other half was 49.0% |
| HY24 share of FY24 EBITDA | 62.8% | — | Other half was 37.2% |
| HY24 share of FY24 NPAT | 57.5% | — | Other half was 42.5% |
| Forward work | $165.0m | $165.0m | +$0.0m |
| Forward work / annualised revenue | 0.68x | 0.58x | — |
| Required CAGR | 16.8% | — | Destination 2030: $530m revenue by FY30 |
| Profit from continuing operations | $4.3m | $4.5m | −$0.1m |
Source: annolyse.ai/briefings/sct-hy25
This analysis was generated using Annolyse, an AI-powered tool that extracts and analyses NZX/ASX company announcements. The underlying data is extracted from official company filings and verified against source documents. This is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.